Clinical Laboratory, Catharina Hospital, Eindhoven, the Netherlands.
Am J Clin Pathol. 2012 Oct;138(4):551-8. doi: 10.1309/AJCPQOD9WFPEYY0H.
The use of direct thrombin inhibitors (DTIs) for prophylactic or therapeutic anticoagulation is increasing because of the predictable bioavailability and short half-life of these DTIs. However, in certain situations, indication of the concentration is warranted. We investigated the effects of 3 DTIs (lepirudin, argatroban, and bivalirudin) in 6 pooled plasma specimens on routine coagulation assays (activated partial thromboplastin time [aPTT], prothrombin time [PT], and thrombin time [TT]) and dedicated DTI assays (Hemoclot, HemosIL, the ecarin clotting time, and a chromogenic ecarin clotting time) on 2 coagulation analyzers. We found routine tests to be nondiscriminative between concentrations of different DTIs in the aPTT. Moreover, for PT and TT, the responses for different DTIs differed. This was similar for ecarin clotting assays. The Hemoclot and HemosIL assays showed identical linear increases for all 3 DTIs. We conclude that dedicated calibrated assays based on a diluted TT (Hemoclot and HemosIL) appear to be the most suitable for monitoring purposes.
由于这些直接凝血酶抑制剂 (DTIs) 的生物利用度可预测且半衰期短,因此它们在预防性或治疗性抗凝中的使用正在增加。然而,在某些情况下,需要指示浓度。我们研究了 3 种 DTIs(lepirudin、argatroban 和 bivalirudin)在 6 种混合血浆标本中对常规凝血检测(活化部分凝血活酶时间 [aPTT]、凝血酶原时间 [PT] 和凝血时间 [TT])和专用 DTI 检测(Hemoclot、HemosIL、蝰蛇凝血时间和发色蝰蛇凝血时间)在 2 种凝血分析仪上的影响。我们发现,在 aPTT 中,常规检测无法区分不同 DTI 的浓度。此外,对于 PT 和 TT,不同 DTI 的反应不同。蝰蛇凝血检测也是如此。Hemoclot 和 HemosIL 检测显示所有 3 种 DTI 的线性增加相同。我们的结论是,基于稀释 TT(Hemoclot 和 HemosIL)的专用校准检测似乎最适合监测目的。